| Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo EvidenceAntitumor Activity of miR-34a in Multiple Myeloma MT Di Martino, E Leone, N Amodio, U Foresta, M Lionetti, MR Pitari, ... Clinical cancer research 18 (22), 6260-6270, 2012 | 243 | 2012 |
| MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches N Amodio, L Raimondi, G Juli, MA Stamato, D Caracciolo, P Tagliaferri, ... Journal of hematology & oncology 11, 1-19, 2018 | 220 | 2018 |
| Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell GrowthAntitumor Activity of mir-21 Inhibitors in Multiple Myeloma E Leone, E Morelli, MT Di Martino, N Amodio, U Foresta, A Gullà, M Rossi, ... Clinical Cancer Research 19 (8), 2096-2106, 2013 | 200 | 2013 |
| miR‐29b negatively regulates human osteoclastic cell differentiation and function: Implications for the treatment of multiple myeloma‐related bone disease M Rossi, MR Pitari, N Amodio, MT Di Martino, F Conforti, E Leone, C Botta, ... Journal of cellular physiology 228 (7), 1506-1515, 2013 | 189 | 2013 |
| miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1 N Amodio, MT Di Martino, U Foresta, E Leone, M Lionetti, M Leotta, ... Cell death & disease 3 (11), e436-e436, 2012 | 176 | 2012 |
| Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity N Amodio, MA Stamato, G Juli, E Morelli, M Fulciniti, M Manzoni, E Taiana, ... Leukemia 32 (9), 1948-1957, 2018 | 172 | 2018 |
| DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma N Amodio, M Leotta, D Bellizzi, MT Di Martino, P D'Aquila, M Lionetti, ... Oncotarget 3 (10), 1246, 2012 | 156 | 2012 |
| Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation L Raimondi, A De Luca, N Amodio, M Manno, S Raccosta, S Taverna, ... Oncotarget 6 (15), 13772, 2015 | 153 | 2015 |
| In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma MT Di Martino, A Gullà, MEG Cantafio, M Lionetti, E Leone, N Amodio, ... Oncotarget 4 (2), 242, 2013 | 152 | 2013 |
| Oncogenic role of the E3 ubiquitin ligase NEDD4-1, a PTEN negative regulator, in non-small-cell lung carcinomas N Amodio, M Scrima, L Palaia, AN Salman, A Quintiero, R Franco, G Botti, ... The American journal of pathology 177 (5), 2622-2634, 2010 | 149 | 2010 |
| Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma S Blotta, J Jakubikova, T Calimeri, AM Roccaro, N Amodio, AK Azab, ... Blood, The Journal of the American Society of Hematology 120 (25), 5002-5013, 2012 | 139 | 2012 |
| Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury T Angelone, E Filice, T Pasqua, N Amodio, M Galluccio, G Montesanti, ... Cellular and molecular life sciences 70, 495-509, 2013 | 134 | 2013 |
| miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies N Amodio, M Rossi, L Raimondi, MR Pitari, C Botta, P Tagliaferri, ... Oncotarget 6 (15), 12837, 2015 | 114 | 2015 |
| Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo E Morelli, E Leone, ME Cantafio, MT Di Martino, N Amodio, L Biamonte, ... Leukemia 29 (11), 2173-2183, 2015 | 112 | 2015 |
| Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity L Raimondi, N Amodio, MT Di Martino, E Altomare, M Leotta, ... Oncotarget 5 (10), 3039, 2014 | 110 | 2014 |
| Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple MyelomamiR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma N Amodio, MA Stamato, AM Gullà, E Morelli, E Romeo, L Raimondi, ... Molecular cancer therapeutics 15 (6), 1364-1375, 2016 | 108 | 2016 |
| miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells N Amodio, D Bellizzi, M Leotta, L Raimondi, L Biamonte, P D’Aquila, ... Cell Cycle 12 (23), 3650-3662, 2013 | 108 | 2013 |
| Early hematopoietic zinc finger protein (EHZF), the human homolog to mouse Evi3, is highly expressed in primitive human hematopoietic cells HM Bond, M Mesuraca, E Carbone, P Bonelli, V Agosti, N Amodio, ... Blood 103 (6), 2062-2070, 2004 | 106 | 2004 |
| Polydatin, a natural precursor of resveratrol, induces cell cycle arrest and differentiation of human colorectal Caco-2 cell S De Maria, I Scognamiglio, A Lombardi, N Amodio, M Caraglia, ... Journal of translational medicine 11 (1), 1-11, 2013 | 105 | 2013 |
| Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts MR Pitari, M Rossi, N Amodio, C Botta, E Morelli, C Federico, A Gullà, ... Oncotarget 6 (29), 27343, 2015 | 101 | 2015 |
Pierfrancesco TassoneProfessor of Medical Oncology, Magna Graecia University, Catanzaro, ItalyVerified email at unicz.it
